Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- ATTR-CM: Concomitant Therapy and Vutrisiran Treatment Effect; New Disease Progression FrameworkConcomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis recently published in JACC.
- Eagle’s Eye View: Can Extreme Heat Impact Blood Pressure?In this week’s View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection.
- Beyond the Tumor: Dyslipidemia Management in Patients With and Survivors of CancerASCVD prevention has historically targeted the general adult population, with survivors of cancer and patients with active cancer being underrepresented. Cancer and its therapies may increase cardiovascular (CV) risk and accelerate vascular disease through treatment-related dyslipidemia...
- ACCEL Lite: Antithrombotic Therapy After TAVIIn this episode, Deepak L. Bhatt MD, MPH, MBA, FACC and Øyvind H. Lie, MD, PhD, MSc examine the results of “ACASA-TAVI: Antithrombotic therapy after TAVIâ€.
- Whole-Grain Intake Tied to Improved Cardiometabolic Risk Factors in Meta-AnalysisHigher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials published Sept. 15 in EHJ. The largest effects were generally seen at whole-grain intakes of about 60-100 g/day.